Abstract
Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was first described as a complication of hepatitis B, this manifestation has been well documented in association with HCV in the setting of liver transplantation, bone marrow transplantation, heart transplantation, and end-stage human immunodeficiency virus infection. We report the clinical course and antiviral response in a patient with FCH due to recurrent hepatitis C after cadaveric liver transplantation who was treated with pegylated interferon alpha-2a and ribavirin.
MeSH terms
-
Antiviral Agents / administration & dosage*
-
Cholestasis, Intrahepatic / diagnosis*
-
Cholestasis, Intrahepatic / pathology
-
Combined Modality Therapy
-
Hepacivirus / drug effects
-
Hepatitis C, Chronic / diagnosis
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / pathology
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage*
-
Liver Transplantation*
-
Male
-
Middle Aged
-
Polyethylene Glycols / administration & dosage*
-
RNA, Viral / analysis
-
Recombinant Proteins
-
Recurrence
-
Ribavirin / administration & dosage*
-
Tomography, X-Ray Computed
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
RNA, Viral
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2a